IFM Therapeutics is a biotechnology company dedicated to developing next-generation small molecule therapies targeting the NLRP3 inflammasome and related innate immune pathways. Founded in 2015, the company has established itself as a leader in NLRP3 biology and drug discovery, with a particular focus on inflammatory and neurodegenerative diseases.
| Attribute | Value |
|---|---|
| Founded | 2015 |
| Headquarters | Boston, Massachusetts, USA |
| CEO | Dr. Gregory Licholai |
| Parent | Subsidiary of Bristol-Myers Squibb (acquired 2020) |
| Focus | NLRP3 and innate immunity modulators |
| Stage | Preclinical/Phase 1 |
IFM Therapeutics was founded by Dr. Gregory Licholai and a team of scientists from Harvard Medical School and Massachusetts General Hospital. The company's founding was based on pioneering research in NLRP3 biology and its role in inflammatory diseases.
In 2020, Bristol-Myers Squibb (BMS) acquired IFM Therapeutics, making it a wholly-owned subsidiary. The acquisition gave BMS access to IFM's NLRP3 pipeline and expertise in innate immunity drug discovery. The company operates as an independent unit within BMS, focusing on NLRP3-related programs for oncology and inflammation.
IFM's platform is built on deep expertise in NLRP3 biology:
| Program | Mechanism | Indication | Stage | Status |
|---|---|---|---|---|
| IFM-2427 | NLRP3 inhibitor | Inflammatory diseases | Preclinical | IND-enabling |
| IFM-3547 | NLRP3/BTK dual | Neurodegeneration | Discovery | Lead optimization |
| IFM-3029 | NLRP3 degrader | Cancer | Discovery | Early stage |
IFM is developing NLRP3 inhibitors specifically for Parkinson's disease:
The company also has programs targeting Alzheimer's disease:
IFM has established collaborations with leading academic centers:
IFM's approach to clinical development includes:
| Company | Strength | Weakness |
|---|---|---|
| IFM (BMS) | Big pharma resources, deep biology | Less CNS-specific focus |
| NodThera | Dedicated CNS, Phase 1 data | Smaller company |
| Olacteant | Clinical data, oral delivery | Limited CNS penetration |
| Novartis | Resources, DFV890 | Broader focus |